A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications (Q6622241)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications |
scientific article; zbMATH DE number 7929484
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications |
scientific article; zbMATH DE number 7929484 |
Statements
A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications (English)
0 references
22 October 2024
0 references
Bayesian adaptive design
0 references
immunotherapy
0 references
optimal biological dose
0 references
platform trial
0 references
risk-benefit tradeoff
0 references
0 references
0 references
0 references
0 references
0 references
